



CALL FOR APPLICATIONS: U.S Hematologists

Applications are due November 18, 2019, by 11:59 PM ET to
<https://htrs.smapply.org>

ITI SCHOOL IN HEMOPHILIA

Lund University Commissioned Education | Centre for Thrombosis and Haemostasis
Friday, January 17 - Saturday, January 18, 2020
Malmö, Sweden

Highlighting the latest knowledge and current challenges of ITI treatment along with different therapeutic options – in an era of new potential approaches to assure the best care of patients who develop inhibitors

The Hemostasis and Thrombosis Research Society (HTRS) is commissioned by Octapharma to recruit and select up to three U.S. hematologists to attend *ITI School in Hemophilia* from January 17-18, 2020, in Malmö, Sweden. This educational course is sponsored by Octapharma and provided by Lund University and the Malmö Centre for Thrombosis and Haemostasis at Skåne University Hospital in collaboration with international hemophilia experts.

HTRS is now accepting applications from U.S. hematologists who can demonstrate a need for further training in the best approaches and care of hemophilia patients who develop inhibitors. Participants should be affiliated with a hemophilia treatment center and have previous ITI experience. Good English skills are required. Successful applicants will travel to Malmö, Sweden to take part in this educational course on January 17-18, 2020.

Course Title:	“ITI SCHOOL IN HEMOPHILIA”
Dates:	Friday, January 17 to Saturday, January 18, 2020
Venue:	Hotel Scandic Triangeln in Malmö, Sweden
Program Format:	This course is based on outlined lectures and interactive authentic case studies in accordance with case methodology. The course includes an examination addressing main messages. Participants will receive a course binder containing the course content

so that the message can be shared with their own departments. LIPUS (Institute for the Professional Development of Physicians in Sweden) will review the course (www.lipus.se). CME (Continuing Medical Education) application pending (EACCME).

Program Description: The 2-day course begins Friday, January 17 at 8:30 a.m. with an introduction and proceeds through a full agenda including lunch and culminating with the Octapharma Symposium and dinner.

On Saturday, January 18, lectures will begin at 8:30 a.m. and presentations, case studies, and the opportunity for interactive discussion will follow, concluding by 4:30 p.m. with an examination and course evaluation.

Applicant Eligibility Requirements

This course is open to U.S. hematologists working in non-commercial institutions who are affiliated with a hemophilia center and have previous ITI experience, and whose careers demonstrate a commitment to hemophilia. Successful applicants will be able to demonstrate some previous clinical experience with hemophilia and explain why additional training will benefit their careers. Good English-speaking skills are required.

Priority will be given to applicants who are current HTRS Core members. To become an HTRS Core member, visit www.HTRS.org.

Expected Outcomes for Course Participants

Development of inhibitory antibodies in hemophilia A and B remains a major complication in the management of patients, jeopardizing the outcome of treatment. The ultimate goal should be tolerization towards the deficient factor by immune tolerance induction (ITI) therapy. These procedures are, however, often complex and associated with several issues. The aim of the course is to highlight latest knowledge, current challenges of ITI treatment and different therapeutic options – in an era of new potential approaches to assure the best care of patients who develop inhibitors.

The scientific content and educational delivery methods for this course are designed by international experts in hemophilia, including members of the Malmö ITI School in Hemophilia faculty such as Jan Astermark (Malmö, Sweden), Pål André Holme (Norway), Carmen Escuriola Ettingshausen (Frankfurt, Germany), Cedric Herman (Brussels, Belgium), Sebastian Lacroix-Desmazes (Paris, France), and Robert F. Sidonio Jr. (Atlanta, Georgia).

Specifically, participants should expect to acquire new knowledge and understanding about:

- Immunology in inhibitor development and ITI
- Therapeutic ITI options to eradicate an inhibitor and induce tolerance
- New and emerging treatment options for patients with inhibitors
- Laboratory methods and pitfalls of measuring inhibitors during ITI
- How to manage and prevent bleedings before and during ITI
- Practical issues in association with ITI and how to manage co-morbidities
- Specific issues to consider in the management of inhibitors in patients with non-severe hemophilia A and severe hemophilia B
- Similarities and differences in pathophysiology and clinical management between acquired and congenital hemophilia

Application Deadline and Submission Instructions

Interested hematologists who can demonstrate ITI experience and are affiliated with a hemophilia treatment center must apply **on or before November 18, 2019 by 11:59 p.m. ET. Please complete the application and upload the components listed below to the HTRS Survey Monkey site at <https://htrs.smapply.org>**. Applicants should click on "Register" and create an account with an email and password. (The site allows you to save your work and return to it later.)

If you do not receive a confirmation email within 48 hours, please email jziegler@versiti.org.

Application Components – please upload all with online application, as follows:

1. **Application Form.** Please visit <https://htrs.smapply.org>, click on Register and create an account with an email and password. Once there, click on the ITI School of Hemophilia program for an application.
2. **Biographical Statement – 500 words or less.** The applicant should provide a biographical statement explaining his or her professional background, education, and career path in hemophilia, including previous clinical experience with ITI.
3. **Rationale for Attending – 500 words or less.** The applicant should explain why attending the course is important to his or her clinical practice and career development in hemophilia.
4. **Mentor Recommendation – 100 words or less.** The applicant's mentor should support the applicant's stated career path and explain why the applicant is a good candidate to participate in the course.
5. **Applicant's NIH Biosketch or Curriculum Vitae**

Please compile all documents and upload within the ITI School in Hemophilia program at the HTRS Survey Monkey Apply site: <https://htrs.smapply.org>.

Notification of Acceptance

All applications will be reviewed by the HTRS Malmö ITI Workshop Course Selection Committee immediately following the **November 18, 2019 deadline**. Applicants will be notified of acceptance via email on or before **Friday, November 22, 2019**. Registration for the conference is due Friday, November 29, 2019.

Covered Expenses

The following expenses will be covered by Octapharma for confirmed course attendees:

1. **Course Registration Fee**
2. **Travel.** Reimbursement will be provided with original receipts for the cost of:
 - Round-trip, business class airline ticket booked by the attendee through the Octapharma travel agent (includes fare and change fee, if incurred). The cost of the ticket should not exceed \$8,000.00.
 - Ground transportation from the airport to the hotel and back
 - Meals on travel days
3. **Lodging.** Reimbursement will be provided for a sleeping room booked by the attendee at the course hotel indicated during registration for the nights of Thursday, January 16, Friday, January 17, and Saturday, January 18, 2020. Additional nights are at the attendee's own expense.
4. **Meals.** The following meals will be provided during the course: lunch and dinner on Friday, January 17, and lunch on Saturday, January 18, 2020. Octapharma will reimburse for meals not included in the course and on travel days.

Disclosure of HTRS Compliance and Reporting Under *Open Payments: The Physician Payments Sunshine Act*

This educational activity is reportable by law under *Open Payments: The Physician Payments Sunshine Act* ("Sunshine Act"). HTRS is required to share information about participating physician attendees with the pharmaceutical company supporter, which deems this information reportable per its policies related to the Sunshine Act.

Applicants are required to confirm that their respective institutions allow them to attend educational events subject to Sunshine Act reporting, since regulations can differ by institution and state.

If you have questions about the Sunshine Act as it pertains to this educational activity, please contact HTRS at htrs@versiti.org.

Course Supporters

"ITI School in Hemophilia" is supported by Octapharma. U.S. attendees' expenses are also covered by Octapharma. HTRS administers the attendee recruitment and selection process.

HTRS Mission

Incorporated as a nonprofit in 1994, HTRS is the leading North American professional society dedicated to research, mentoring, workforce development, and continuing medical education for physicians, investigators, and all health care professionals interested in advancing care for people with hemostatic and thrombotic disorders. For information on HTRS educational and grant opportunities in non-malignant hematology, visit www.htrs.org.

Questions

With questions and additional info, please contact:
Jennifer Ziegler
Director, Awards Programs and Marketing
Hemostasis and Thrombosis Research Society (HTRS)
(414) 477-6130
jziegler@versiti.org

We look forward to hearing from our future leaders in hemophilia and ITI!

Sincerely,

The Malmö VWD Course Selection Committee

Shannon L. Meeks, MD – Chair
Malmö ITI School of Hemophilia Selection Committee
Emory University/Children's Healthcare of Atlanta

Stacy E. Croteau, MD, MMS
Malmö School of Hemophilia Selection Committee
Boston Hemophilia Center, Harvard Medical School

Christopher Ng, MD
Malmö ITI School of Hemophilia Selection Committee
University of Colorado Hemophilia and Thrombosis
Center, Children's Hospital Colorado

Allison Paroskie Wheeler, MD, MSCI
Malmö School of Hemophilia Course Selection Committee
Vanderbilt University

